Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen aMJEVITA / AMGEVITA (adalimumab-atto — Humira Biosimilar) — U.S. product sales ($M) ($M)
Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail
Latest, FY2025
48
Period ended Dec 31, 2025
Change on a year earlier
-76.2%
202 in FY2024
History
3 years
Since FY2023
Sources
3
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | AMJEVITA / AMGEVITA (adalimumab-atto — Humira Biosimilar) — U.S. product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 48 | -76.2% | Form 10-K (amgn-20251231.htm, filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | 202 | +60.3% | Form 10-K (amgn-20241231.htm, filed 2025-02-14) ↗ |
| FY2023 | Dec 31, 2023 | 126 | – | Form 10-K (amgn-20231231.htm, filed 2024-02-14) ↗ |
Cite this data
StockData. (2026). Amgen AMJEVITA / AMGEVITA (adalimumab-atto — Humira Biosimilar) — U.S. product sales ($M) ($M), annual FY2023–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod_amjevita_us
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.